PURCHASE, N.Y--June 12, 2002--Nutrition 21 (NASDAQ: NXXI), Gail Montgomery, President and CEO of Nutrition 21, announced today the publication of a study conducted by William Cefalu, MD at the University of Vermont College of Medicine, in this month's Journal of Nutrition.
Dr. Cefalu and colleagues evaluated the differences in carbohydrate and lipid metabolism between obese and lean animals. The researchers found that the obese animals had impaired metabolism and that the administration of chromium picolinate significantly improved both carbohydrate and lipid metabolism in these animals. The enhanced metabolism resulted in superior blood sugar control and cholesterol profiles (e.g., reduced total cholesterol levels, and increased HDL cholesterol levels). In addition, the researchers found that the intake of chromium picolinate resulted in a significant improvement in the metabolic action of muscle cells.
"These results further clarify chromium's essential role in metabolism and support the data seen in our earlier clinical studies showing accelerated weight and fat loss, reduction of elevated blood glucose levels and improved cholesterol profiles in overweight individuals. Our company's new business strategy is intimately linked to the emerging scientific evidence supporting chromium's essential metabolic functions in both diabetic and overweight populations," Ms. Montgomery commented.
About Nutrition 21
Nutrition 21 is a leading developer and marketer of nutritional products whose health benefits have been substantiated by clinical research. The market leader in nutritional chromium, Nutrition 21 currently holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com.
Safe Harbor Provision
The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission. Actual results can differ materially. The company makes no commitment to disclose any revisions to forward-looking statements.